Increasing Competitiveness through innovation in biotechnology

This page is under construction and edited by Murat Akguc EMBA09. In case of any questions/remarks, feel free to contact me

Description:

As companies face pressure from increased competition, shortening product life cycles and growing product complexity many are finding they need to change the way they develop new technologies, products and services.

Biotechnology is of growing importance to pharmaceutical research. An increasing number of innovative medicines have their origin in biotechnological research, i.e. the use of living organisms or their derivatives for therapeutic purposes, rather than chemical substances as in modern pharmacological treatment. As these products are extremely complicated and expensive to develop and test, it is necessary create an environment that rewards innovation and removes unnecessary regulatory, administrative or economic obstacles.

Biotechnology has become the driving force of radical changes in innovation processes in various sectors. This is best illustrated by the pharmaceutical industry where the traditional chemical paradigm of drug discovery and development is being replaced by a new biotechnological paradigm. This has important consequences for the structure and functioning of the biopharmaceutical innovation system: biotechnology firms and public sector research organisations are becoming key actors generating new knowledge, tools and substances for the pharmaceutical industry. Regulations, standards and intellectual property rights (IPR) schemes have to deal with new types of components, and, on the demand side, new solutions are emerging for as yet unmet needs.

Enablers:

Factors which strengthen this driving force. (these are actually other driving forces, and you can link to them in the wiki!)

Inhibitors:

Factors which weaken this driving force. (these are actually other driving forces, and you can link to them in the wiki!)

Paradigms:

Changes in ways of thinking about the world due to the driving force.

Experts:

Sources for additional information about this driving force. (if you have found people, put the links to them)

Timing:

Dates for key milestones in the development of the driving force.

Web Resources:

• Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level, OECD, 2006 (http://www.oecd.org/document/55/0,3343,en_2649_34273_36446711_1_1_1_1,00.html)

• Sustaining Competitiveness through Alliances and Innovation: The impact of Alliance Management Issues on learning skills and competencies from partner(s), Prof. S. Raghunath (Email), Thomas Joseph (Email), (http://dspace.iimk.ac.in/bitstream/2259/492/1/349-358+.pdf)

• European Commission - Enterprise and Industry Directorate General - Consumer goods - (http://ec.europa.eu/enterprise/phabiocom/index_en.htm)